What is Attovia?
Attovia Therapeutics is a pioneering biotechnology firm dedicated to the development of next-generation biotherapeutics. At the core of its innovation is the ATTOBODY platform, a proprietary technology designed to generate biparatopic biologics. By utilizing spatial positioning technology, these molecules achieve picomolar affinity and superior potency compared to traditional IgG-based medicines. The company's modular approach allows for tunable half-lives and high-throughput discovery, effectively derisking the development process while expanding the range of treatable biological targets. Attovia is strategically positioned to address significant unmet needs in immunology through its nimble, evolution-based discovery engine.
How much funding has Attovia raised?
Attovia has raised a total of $484M across 3 funding rounds:
Series B
$105M
Series C
$90M
IPO
$289M
Series B (2024): $105M with participation from Nextech Ventures, Cormorant Asset Management, and Goldman Sachs
Series C (2025): $90M led by Frazier Life Sciences Management, Deep Track Capital, Illumina Ventures, EcoR1 Capital, Nextech Venture, Sanofi Ventures, GOLDMAN SACHS GROUP, Marshall Wace, Vida Ventures, venBio Partners, Cormorant Asset Management, and Mirae Asset Capital
IPO (2026): $289M, investors not publicly disclosed
Key Investors in Attovia
Frazier Life Sciences Management
A longstanding biotech investment firm that employs both venture and public strategies to partner with and build companies focused on developing novel therapeutics.
Cormorant Asset Management
A prominent life sciences investment firm driven by a deep focus on fundamental scientific principles, supporting innovative private and public companies.
Goldman Sachs
A leading global investment banking and management firm providing strategic advisory, financing, and capital market expertise to high-growth enterprises.
What's next for Attovia?
Following its recent major strategic investment, Attovia Therapeutics is poised to accelerate its clinical pipeline and scale its discovery operations. The company's trajectory, marked by consistent backing from top-tier life sciences investors, suggests a focus on advancing lead candidates toward late-stage clinical trials. With the modularity of the ATTOBODY platform, Attovia is well-positioned to explore multispecific applications and optimize dosing regimens, potentially setting a new standard for patient care in chronic immune conditions. Future strategic efforts will likely prioritize the expansion of its therapeutic footprint and the strengthening of its intellectual property portfolio to maintain a competitive edge in the global biopharma market.
See full Attovia company page
